Оптимизация ведения пациентов с язвенной болезнью желудка и двенадцатиперстной кишки в амбулаторной практике по данным фармакоэпидемиологического анализа
Диссертация
С учетом вышеизложенного, представляется необходимым выявить реальную ситуацию с диагностикой и лечением ЯБ в России. В нашей стране существует особенности ведения пациентов с данной патологией. Возможно, это связано с отсутствием во многих лечебных учреждениях возможности адекватной диагностики Н. pylori до и после проведенной эрадикационной терапии, или использованием методов с малой… Читать ещё >
Список литературы
- Аруин Л.И., Капуллер Л. Л., Исаков В. А. Морфологическая диагностика болезней желудка и кишечника. — Москва: Триада-Х, 1998. — 236 с.
- Говорун В.М., Гущин А. Е., Исаков В. А. и др. Молекулярная диагностика и генотипирование H.pylori в биоптатах слизистой оболочки желудка // Рос. журн. гастроэнтерол., гепатол., колопроктол. 2000. — № 2. — С. 1215.
- Заболеваемость населения России в 2003 году: статистические материалы. Часть I. М.: ГЭОТАР-МЕД, 2004. — 124 с.
- Зверков И.В., Исаков В. А., Аруин Л.И. Helicobacter pylori, эндокринные клетки слизистой оболочки желудка и их функция при язвенной болезни двенадцатиперстной кишки // Арх. патол. 1996. № 1. — С. 33−37.
- Ивашкин В.Т., Лапина Т. Л. Гастроэнтерология XXI века // РМЖ. 2000. -№ 17.-С. 697−703.
- Исаков В.А., Домарадский И. В. Хеликобактериоз. М.: ИД
- Медпрактика-М, 2003. 412 с.
- Ковалев Н.А., Аванян H.JL, Тимченко Н. А. Сравнительная оценка уреазного теста и цитологического исследования в диагностике инфекции H. pylori II Рос. журн. гастроэнтерол., гепатол., колопроктол.1999.-Т. 9, № 5.-С. 29−31.
- Кудрявцева Л.В., Исаков В. А., Иванников И. О. и др. Резистентность Н. pylori к метронидазолу, кларитромицину и амоксициллину в Москве, Санкт-Петербуге и Абакане в 2001 году // Педиатрия. 2002. — № 2. — С. 61−63.
- Курилович С.А., Решетников О. В. Эпидемиология заболеваний органов пищеварения в Западной Сибири // Педиатрия. 2002. — № 2. — С. 65−71.
- Лапина Т.Л. Рекомендации по лечению инфекции Helicobacter pylori II РМЖ. 1998. — № 6. — С. 419−425.
- Лапина Т.Л. Язвенная болезнь желудка и двенадцатиперстной кишки // Consilium medicum. 2004. — Т. 4, № 1. — С. 12−17.
- Маев И.В., Самсонов А. А. Язвенная болезнь двенадцатиперстной кишки: различные подходы к современной консервативной терапии // Consilium medicum. 2004. — № 1. — С. 6−11.
- Окороков А.И. Диагностика болезней внутренних органов: Практ. рук. В 4 т. Т 1.-М.: Мед. лит., 1999. 560 е.: ил.
- Окороков А.И. Лечение болезней внутренних органов: Практ. рук. В 3 т. Т 1 2-е изд., перераб. и доп. Мн.: Выш. шк., 1997. — 552 е.: ил.
- Пиманов С.И. Эзофагит, гастрит и язвенная болезнь. М.: Мед кн.2000. 144 с.
- Рекомендации по диагностике Helicobacter pylori у больных с язвенной болезнью и методам их лечения // Рос. журн. гастроэнтерол., гепатол., колопроктол. 1998.-№ 1.-С. 105−107.
- Решетников О.В., Курилович С. А. Встречаемость Н. pylori в Сибире по данным серологического исследования // Микробиол. эпидемиол. иммунол. 2000. — № 3. — С. 32−34.
- Сидоренко С.В. Диагностика и лечение инфекций, вызываемых Helicobacter pylori II Антибиотики и химиотерапия. 2001. — Т. 46, № 8. -С. 23−31.
- Сугоняко Е.А., Цуканов В. В. Частота осложнений язвенной болезни в России // Рос. журн. гастроэнтерол., гепатол., колопроктол. 2005. -Приложение № 26. — С. 58.
- Шкитин В.А., Шпирна А. И., Старовойтов Г. Н. Роль Helicobacter pylori в патологии человека // Клин, микробиол. и антимикроб, химиотер. -2002.-Т. 4, № 2.-С. 128−146.
- Щербаков П.Л. Эпидемиология инфекции Helicobacter pylori. II В кн. Ивашкин В. Т., Мегро Ф., Лапина Т. Л., ред. Helicobacter pylori: революция в гастроэнтерологии. М.: Триада-Х, 1999. — С. 14−20.
- Alarcon Т., Domingo D., Sanchez I. et al. In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori II Eur. J. Clin. Microbiol. Infect. Dis. 1996. — Vol. 15, N 12.-P. 937−940.
- Antibiotic Policies: Theory and Practice / Edited by I.M. Gould, J.W. van der Merr. New York: Plenum Publishers, 2005. — 458 p.
- Auroux J., Lamarque D., Tankovic J. et al. Comparison of quantifying Helicobacter pylori gastric infection by culture, histology and С13 urea breath test (see comments) // Gastroenterol. Clin. Biol. 1998. — Vol. 22, N 4. — P. 407−412.
- Bardhan K.D., Dekkers C.P., Lam S.K. et al. GR12231IX (ranitidine bismuth citrate), a new drug for the treatment of duodenal ulcer // Aliment. Pharmacol. Ther. 1995. — Vol. 9, N 5. — P. 497−506.
- Bierer D.W. Bismuth subsalicylate: history, chemistry, and safety // Rev. Infect. Dis. 1990. — Vol. 12. — P. 3−8.
- Bode G., Mauch F., Malfertheiner P. The coccoid forms of Helicobacter pylori. Criteria for their viability // Epidemiol. Infect. 1993. — Vol. 111. — P. 483−490.
- Boyanova L., Mentis A., Gubina M. et al. The status of antimicrobial resistance of Helicobacter pylori in Eastern Europe // Clin. Microbiol. Infect. 2002. — Vol. 8, N 7. — P. 388−396.
- Burton A., Bonn D. Helicobacter pylori very old // The Lancet Infect. Dis. -2003.-Vol.3.-P. 6−9.
- Candelli M., Nista E.S., Carloni E. Treatment of Helicobacter pylori infection: a review // Curr. Med. Chem. 2005. — Vol. 12, N 4. — P. 375−384.
- Chowers M.Y., Keller N., Tal R. et al. Human gastrin: a Helicobacter pylori-specific growth factor // Gastroenterology. 1999. — Vol. 117. — P. 1113−1118.
- Dominici P., Bellentani S., Di Biase A.R. et al. Familial clustering of
- Helicobacter pylori infection: population based study // BMJ. 1999. — Vol. 319. — P. 537−541.
- Endo H., Tsukamoto Y., Arisawa T. et al. Effects of intragastric ammonia on collagen metabolism of gastric ulcer base in rats // Digestion. 1996. — Vol. 57.-P. 411−419.
- Erah P.O., Goddard A.F., Barrett D.A. et al. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection // J. Antimicrob. Chemother. 1997. — Vol. 39, N 1. -P. 5−12.
- Gatta L. et al. Non-invasive techniques for the diagnosis of Helicobacter pylori infection I I Clin. Microbiol. Infect. 2003. — Vol. 9. — P. 489−496.
- Gisbert G.P., Pajares J.M. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? // Aliment. Pharmacol. Ther. 2005. — Vol. 21, N 7. — P. 795−804.
- Glupczynski Y. Culture of Helicobacter pylori from gastric biopsies and antimicrobial susceptibility testing / In: Lee A., Megraud F. editors.
- Helicobacter pylori: techniques for clinical diagnosis and basic research. -London: Saunders, 1996. P. 17−32.
- Goddard A.F., Spiller R.C. The effect of omeprazole on gastric juice viscosity, pH and bacterial counts // Aliment. Pharmacol. Ther. 1996. — Vol. 10, N 1. — P. 105−109.
- Goodwin C.S., McCulloch R.K., Armstrong J.A., Wee S.H. Unusual cellular fatty acids and distinctive ultra-structure in a new spiral bacterium {Campylobacter pylori) from the human gastric mucosa // J. Med. Microbiol. 1987.-Vol. 19.-P. 257−267.
- Gooz M., Hammond C.E., Larsen K., Mukhin Y.V., Smolka A.J. Inhibition of human gastric H±K±ATPase-subunit gene expression by Helicobacter pylori IIAJP. 2000. — Vol. 278, N 6. — P. 981 -991.
- Ge Z., Taylor D.E. Helicobacter pylori molecular genetics and diagnostic typing // Br. Med. Bull. 1998. — Vol. 54, N 1. — P. 31−38.
- Hall D.W., van den Hoven W.E. Gastric mucosa protection and prostaglandin E2 generation in rats by colloidal bismuth subcitrate // Arch. Lnt. Pharmacodyn. Ther 1987. — Vol. 286, N 2. — P. 308−319.
- Henriksson A.E., Edman A.C., Nilsson I., Bergquist D., Wadstrom T. Helicobacter pylori and the relation to other risk factors in patients with acute bleeding peptic ulcer // Scand. J. Gastroenterol. 1998. — Vol. 33. — P. 10 301 033.
- Hildebrand P., Bardhan P. et al. Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults // Gastroenterol.-2001.-Vol. 121, N4.-P. 792−798.
- Hildebrand P., Meyer-Wyss B.M., Mossi S., Beglinger C. Risk among gastroenterologists of acquiring Helicobacter pylori infection: case-controlstudy // BMJ. 2000. — Vol. 321. — P. 149−152.
- Itoh Т., Yanagawa Y., Shingaki M. et al. Isolation of Campylobacter pyloridis from human gastric mucosa and characterization of the isolates // Microbiol. Immunol. 1987. — Vol. 31, N7.-P. 603−614.
- Joish V.N., Donaldson G., Stockdale W. et al. The economic impact of GERD and PUD: examination of direct and indirect cost using a large integrated employer claims database // Curr. Med. Res. Opin. 2005. — Vol. 21, N 4. — P. 535−544.
- Kalia N., Jacob S., Brown N.J. et al. Studies on gastric mucosal microcirculation. Helicobacter pylori water soluble extracts induce platelet aggregation in gastric mucosal microcirculation in vivo // Gut. 1997. — Vol. 41.-P. 748−752.
- Kohly Y., Kato Т., Azuma T. et al. Lansoprazole treatment for Helicobacter /^/orz'-positive peptic ulcers // J. Clin. Gastroenterol. 1995. — Vol. 20, N 2. -P. 112−114.
- Konagaya Т., Kusugami K., Nishio Y. et al. Negative correlation between somatostatin levels and interleukin-8 activity in gastric antral mucosa // Gut.1997.-Vol. 41.-P. 24−27.
- Konturek J.W., Konturek S.J. Domschke W. Eradication of Helicobacter pylori restores the inhibitory effect of cholecystokinin on gastric motility in duodenal ulcer patients // Gut. 1997. — Vol. 41. Suppl. 1. — P. 16.
- Konturek S.J., Bilski J., Kwiecien N. et al. De-Nol stimulates gastric and duodenal alkaline secretion through prostaglandin dependent mechanism // Gut. 1987. — Vol. 28, N 12. — P. 1557−1563.
- Konturek S.J., Radecki Т., Piastucki I., Drozdowicz D. Studies on the gastroprotective and ulcer-healing effects of colloidal bismuth subcitrate // Digestion. 1987. — Vol. 37, N 2. — P. 8−15.
- Konturek S.J., Radecki Т., Piastucki L. et al. Gastrocytoprotection by colloidal bismuth subcitrate (De-Nol) and sucralfate. Role of endogenous prostaglandins // Gut. 1987. — Vol. 28, N 2. — P. 201−205.
- Kuipers E.J. Helicobacter pylori, MALT lymphoma and gastric cancer // J. Chemther. 1999. -Vol. 11, N2.-P. 25−28.
- Kwon D.H., Hulten K., Kato M. et al. DNA sequence analysis of rdxA and frxA from 12 pairs of metronidazole-sensitive and -resistant clinical Helicobacter pylori isolates // Antimicrob. Agents Chemother. 2001. — Vol. 45, N9.-P. 2609−2615.
- Lambert J.R., Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection // Aliment. Pharmacol. Ther. 1997. — Vol. 11, N l.-P. 27−33.
- Laszewicz W., Gabryelewicz A., Zaremba-Woroniecka A. Helicobacter pylori infection and gastric secretion in duodenal and gastric ulcer patients -the effect of eradication after one year // J. Physiol. Pharmacol. 1997. — Vol. 48.-P. 353−364.
- Lehmann F.S., Golodner E.H., Wang J. et al. Mononuclear cells and cytokines stimulate gastrin release from canine antral cells in primary culture // Am. J. Physiol. 1996. — Vol. 270, N 5. — P. 783−788.
- Levenstein S. Stress and peptic ulcer: life beyond Helicobacter II BMJ. -1998.-Vol. 316.-P. 538−541.
- Lind Т., Veldhuyzen van Zanten S., Unge P. et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study // Helicobacter. 1996. — Vol. 1, N 3. — P. 138−144.
- Logan R.P., Walker M.M., Misiewicz J.J., Gummett P.A., Karim Q.N., Baron J.H. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole // Gut. 1995. — Vol. 36, N 1. — P. 12−16.
- Louw J. A., Marks I.N. The management of peptic ulcer disease // Curr. Opin. Gastroenterol. 2003. — Vol. 19, N 2. — P. 533−539.
- MacMahon B.J., Hennessy T.N., Bensler J.M. et al. The Relationship among Previous Antimicrobial Use, Antimicrobial Resistance, and Treatment Outcomes for Helicobacter pylori Infections // Ann. Intern. Med. 2003. -Vol. 139, N6.-P. 463−469.
- Malfertheiner P, Megraud F, O’Morain C. et al. Current concepts in the management of Helicobacter pylori infection the Maastricht 2−2000 Consensus Repot // Aliment. Pharmacol. Ther. — 2002. — Vol. 16, N 2. — P. 167−180.
- Marais A., Monteiro L., Occhialini A. et al. Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens // Gut. 1999. — Vol. 44, N 4. — P. 463−467.
- Martins A.P., Miranda A.C., Mendes Z., Soares M.A., Ferreira P. Self-medication in a Portuguese urban population: a prevalence study // Pharmacoepidemiology and drug safety. 2003. — Vol. 12. — P. 27−28.
- McColl K.E.L. Helicobacter pylori, gastric acid, and duodenal gastric metaplasia//Gut. 1996. — Vol. 39.-P. 615−616.
- Megraud F., Bonnet F., Gamier M., Lamouliatte H. Characterization of «Campylobacter pyloridis» by culture, enzymatic profile, and protein content // J. Clin. Microbiol. 1985. — Vol. 22, N 6. — P. 1007−1010.
- Melchers K., Herrmann L., Mauch F. et al. Properties and function of the P type ion pumps cloned from Helicobacter pylori II Acta. Physiol. Scand. -1998.-Vol. 643.-P. 123−135.
- Meucci G., Di Battista R., Abbiati C. et al. Prevalence and risk factors of Helicobacter pylori-negative peptic ulcer: a multicenter study // J. Clin. Gastroenterol. 2000. — Vol. 31, N 1. — P. 42−47.
- Michetti M., Kelly C.P., Kraehenbuhl J.P., Bouzourene H., Michetti P. Gastric mucosal 47-integrinpositive CD4 T lymphocytes and immune protection against Helicobacter infection in mice 11 Gastroenterology. 2000. -Vol. 119.-P. 109−118.
- Midolo P.D., Turnidge J.D., Lambert J.R. Bactericidal activity and synergy studies of proton pump inhibitors and antibiotics against Helicobacter pylori in vitro // J. Antimicrob. Chemother. 1997. — Vol. 39, N 3. — P. 331−337.
- Mistiaen W., Van Нее R., Bortier H. Current status of proximal gastric vagotomy, one hundred years after Pavlov: is it finally history? // Acta. Chir. Belg. 2005. — Vol. 105, N 2. — P. 121−126.
- Mobley H. The role of Helicobacter pylori urease in the pathogenesis of gastritis and peptic ulceration // Alim. Pharmacol. Ther. 1996. — Vol. 10. — Suppl. l.-P. 57−64.
- Morgan D.R., Freedman R., Depew C.E., Kraft W.G. Growth of Campylobacter pylori in liquid media // J. Clin. Microbiol. 1987. — Vol. 25, N 11.-P. 2123−2125.
- Moron A.P. The role of lipopolysaccharide in Helicobacter pylori pathogenesis I I Aliment. Pharmacol. Ther. 1996. — Vol. 10. Suppl. l.-P. 3950.
- Murakami K., Fujioka Т., Kodama R. et al. Helicobacter pylon infection accelerates human gastric mucosal cell. proliferation // J. Gastroenterol. -1997.-Vol. 32.-P. 184−188.
- Ochman H., Moran N.A. Genes lost and genes found: evolution of bacterial pathogenesis and symbiosis // Science. 2001. — Vol. 22, N 19. — P. 10 961 099.
- Peek P.M., Moss S.F., Tham K.T. et al. Helicobacter pylori cagA+ strains anddissociation of gastric epithelial N cell proliferation from apoptosis // J. Natl. Cancer. Inst. 1997. — Vol. 89. — P. 863−868.
- Perri F., Festa V., Merla A. et al. Amoxicillin / tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection // Helicobacter. 2002. — Vol. 7, N 2. — P. 99−104.
- Peterson W.L. Gastrin and acid in relation to Helicobacter pylori II Aliment. Pharmacol. Ther. 1996. — Vol. 10. Suppl. 1. — P. 97−102.
- Queiroz D.M., Mendes E.N., Rocha G.A. et al. Effect of Helicobacter pylori eradication on antral gastrin and somatostatin-immunoreactive cell density and gastrin and somatostatin concentrations // Scand. J. Gastroenterol. 1993. -Vol. 28.-P. 858−864.
- Raiha I., Kemppainen H., Kaprio J. et al. Lifestyle, stress, and genes in peptic ulcer disease: a Nationwide Twin Cohort Study // Arch. Intern. Med. 1998. -Vol. 158.-P. 698−704.
- Rupnow M.F., Shachter R.D., Owens D.K., Parsonnet J. A dynamic transmission model for predicting trends in Helicobacter pylori and associated diseases in the United States // Emerg. Infect. Dis. 2000. — Vol. 6, N 3. — P. 228−237.
- Scott D., Weeks D., Melchers K., Sachs G. The life and death of Helicobacter pylori II Gut. 1998. — Vol. 43. — Suppl. 1. — P. 56−60.
- Shehy O., Letorier J. The use of H. pylori eradication drugs in Canada // Pharmacoepidemiology and drug safety. 2000. — Vol. 9, N 1. — P. 69−70.
- Sipponen P. Peptic ulcer disease / In: Whitehead R, editor. Gastrointestinal and oesophageal pathology. 2nd ed. London: Churchill Livingstone, 1995. -P. 512−523.
- Sox Т.Е., Olson С.A. Binding and killing of bacteria by bismuth subsalicylate // Antimicrob. Agents Chemother. 1989. — Vol. 33, N 12. — P. 2075−2082.
- Stolte M., Kroher C., Meining A. et al. A comparison of Helicobacter pylori and H. heilmannii gastritis. A matched control study involving 404 patients // Scand. J. Gastroenterol. 1997. — Vol. 32. — P. 28−33.
- Stratton C.W. Mechanisms of action for antimicrobial agents: general principles and mechanisms for selected classes of antibiotics / In: Lorian V. Antibiotics in Laboratory Medicine, fourth edition. Baltimore: Williams & Wilkins, 1996.-P. 579−603.
- Sugamata M., Ihara Т., Todate A. et al. Ultrastructural study of antral G cells in patients with duodenal ulcers: effect of Helicobacter pylori eradication // Helicobacter. 1997. — Vol. 2. — P. 118−122.
- Sullivan B. et al. Azithromycin is not effective for eradication of Helicobacter pylori II Am. J. Gastroenterology. 2002. — Vol. 97. — P. 2536−2539.
- Sumii M., Sumii K., Tari A. et al. Expression of antial gastrin and somatostatin mRNA in Helicobacter pylori-infected subjects // Am. J. Gastroenterol. 1994. — Vol. 89. — P. 1515−1519.
- Terada S., Negayama K., Kawanishi K. Neutrophil migration into the mucous layer in Helicobacter pylori associated gastritis // Eur. J. Gastroenterol. Hepatol. 1993. — Vol. 5, N 1. — P. 45−49.
- Tokunaga Y., Shirahase H., Yamamoto E. et al. Semiquantitative evaluation for diagnosis of Helicobacter pylori infection in relation to histological changes II Am. J. Gastroenterol. 1998. — Vol. 93, N 1. — P. 26−29.
- Treiber G., Ammon S., Klotz U. Proton-pump-inhibitor and amoxycillin interaction in vivo II Gut. 1997. — Vol. 41, N 1. — P. 91−96.
- Trevisani L., Sartori S., Galvani F. et al. Evaluation of a new enzymeimmunoassay for detecting Helicobacter pylori in feces: a prospective pilot study // Am. J. Gastroenterol. 1999. — Vol. 94, N 7. — P. 1830−1833.
- Vaara M., Vaara T. Polycations as outer membrane-disorganizing agents // Antimicrob. Agents Chemother. 1983. — Vol. 24. — P. 114−122.
- Vaira D., Malfertheiner P., Megraud F. et al. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group // Am. J. Gastroenterol. 2000. — Vol. 95, N 4. — P. 925−929.
- Versolavic J., Lewandrowski K. Helicobacter pylori Update // Clin. Microbiol. News. 2000. — Vol. 20, N 13. — P. 107−113.
- Wan den Brink G.R., ten Kate F.J., Ponsioen C.Y., Rive M.M., Tytgat G.N., van Deventer S.J., Peppelenbosch M.P. Expression and Activation of NF-B in the Antrum of the Human Stomach // J. Immunology. 2000. — Vol. 164. — P. 3353−3359.
- Webb P. M., Crabtree J. E., Forman D. and the Eurogast. Study Group. Gastric Cancer, Cytotoxin-associated gene A-positive Helicobacter pylori, and serum pepsinogens: an international study // Gastroenterology. 1999. -Vol. 116.-P. 269−276.
- Weigert N., Schaffer K., Schusdziarra V. et al. Gastrin secretion from primary cultures of rabbit antral G cells: stimulation by inflammatory cytokines // Gastroenterology. 1996. — Vol. 110. — P. 147−154.
- William M., Jeremy S., Pruckler J., Sond Q. et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori infected persons, United States // Emerg. Infect. Dis. — 2004. — Vol. 10, N 6. — P. 1088−1099.
- Williams C.L. Helicobacter pylori: bacteriology and laboratory diagnosis // J. Infect. 1997. — Vol. 34. — P. 1−5.
- Yoshida N., Granger D.N., Evans D.G. et al. Mechanisms involved in Helicobacter pylori-induced inflammation // Gastroenterology. 1993. — Vol. 105.-P. 1431−1440.
- Zavros Y., Reider G., Ferguson A. et al. Hypergastrinemia in response to gastric inflammation suppresses somatostatin // Am. J. Physiol. Gastrointest. Liver Physiol. 2002. — Vol. 282. — P. 175−183.
- Zhang Q.B., Nakshabendi I.M., Mokhashi M.S. et al. Association of cytotoxinproduction and neutrophil activation by strains of Helicobacter pylori isolated from patients with peptic ulceration and chronic gastritis // Gut. 1996. — Vol. 38.-P. 841−845.